ライフサイエンスコーパス: multiorgan

1 (range, 5-93) from liver (12), heart (4), or multiorgan (1) transplantation.

2 neurodegenerative epilepsy and results from multiorgan accumulations, termed Lafora bodies (LB), of

3 mmunohistochemistry was performed using both multiorgan- and in-house-constructed pancreatic tissue m

4 ent susceptibility to infections, as well as multiorgan atopy and autoimmunity.

5 appab1(-/-)) develop lymphoproliferative and multiorgan autoimmune disease attributed in large part t

6 even wild-type CD3 ITAMs developed a lethal, multiorgan autoimmune disease caused by a breakdown in c

7 or mice, central tolerance is incomplete and multiorgan autoimmune disease results.

8 Importantly, these mice also develop a multiorgan autoimmune disease with autoantibodies agains

9 Surprisingly, we did not detect multiorgan autoimmune disease.

10 the autoimmune regulator (aire) gene develop multiorgan autoimmune disease.

11 hogenic mechanisms mediating inflammation in multiorgan autoimmune diseases may vary between the diff

12 , role in the development of organ damage in multiorgan autoimmune diseases.

13 IgG4-RD is a multiorgan autoimmune disorder characterized by fibrous

14 inopathy-candidiasis-ectodermal dystrophy, a multiorgan autoimmune disorder rooted in a lesion in thy

15 -beta signaling (TGF-betaRIIDN mice) display multiorgan autoimmune disorders.

16 -Tgfbr2 KO mice die before 15 wk of age with multiorgan autoimmune inflammation and spontaneous activ

17 onstrated a novel role of IL-2 in regulating multiorgan autoimmune inflammation beyond the Treg check

18 Unlike the indiscriminate multiorgan autoimmune phenotype of the corresponding kno

19 L-2 and CD95 (Fas) signaling pathways in the multiorgan autoimmune syndrome beyond the Treg checkpoin

20 D4+Foxp3+ regulatory T cells (Tregs), severe multiorgan autoimmune syndrome, and early death at 4 wk

21 n T cells engendered aggressive early-onset, multiorgan, autoimmune-associated lesions with 100% mort

22 ving lymphadenopathy, autoimmune cytopenias, multiorgan autoimmunity (lung, gastrointestinal, hepatic

23 w is necessary and sufficient to prevent the multiorgan autoimmunity characteristic of Aire-deficient

24 ral nervous system and is a component of the multiorgan autoimmunity syndrome that results from Aire

25 ntial in the perinatal period to prevent the multiorgan autoimmunity that is typical of Aire deficien

26 nrecognized role for NFkappaB1 in preventing multiorgan autoimmunity through its negative regulation

27 The patients displayed multiorgan autoimmunity, lymphoproliferation, and delaye

28 ciency in FOXP3(+) T cells results in lethal multiorgan autoimmunity.

29 Both humans and mice lacking Aire develop multiorgan autoimmunity.

30 dy deficiency, infection susceptibility, and multiorgan autoimmunity.

31 congenitally athymic mice frequently develop multiorgan autoimmunity.

32 rance, and their deficiency results in fatal multiorgan autoimmunity.

33 A patient with multiorgan autoinflammation, combined immunodeficiency,

34 antibodies against a multitude of organs and multiorgan autoinflammatory infiltrates.

35 yotonic dystrophy, as a robust suppressor of multiorgan breast cancer metastasis.

36 Despite the presence of multiorgan chronic inflammation, aged VISTA-deficient mi

37 ed disease (IgG4-RD) is a poorly understood, multiorgan, chronic inflammatory disease characterized b

38 e, HIES) is a complex immune deficiency with multiorgan clinical manifestations and diverse genetic b

39 This amplifies multiorgan complications because BMSCs promote vascular

40 These multiorgan defects are attenuated by platelet depletion

41 ll platelets in vivo markedly attenuates the multiorgan defects, suggesting that platelet lysosome se

42 l syndrome including embryonic lethality and multiorgan defects.

43 g demographics and epidemiology, the role of multiorgan deficiencies, potential mechanisms that invol

44 mbryonic day 11.5 by affecting placental and multiorgan development.

45 g of the endoderm generate a highly ordered, multiorgan digestive system in vertebrate animals.

46 Cystic fibrosis (CF) is a multiorgan disease caused by loss of a functional cystic

47 Alcohol dependence (AD) is a multiorgan disease in which excessive oxidative stress a

48 Hypertension is a perplexing multiorgan disease involving renal primary pathology and

49 VHL is a complex, multiorgan disease that spans the breadth of oncology su

50 in genes, resulting in chronic hemolysis and multiorgan disease that ultimately leads to premature de

51 uberous sclerosis complex (TSC) is a genetic multiorgan disorder characterized by the development of

52 The patients had a multiorgan disorder that included congenital nephrotic s

53 s of functional alpha3beta1, causing a fatal multiorgan disorder.

54 tivity in human cell lines and virulence and multiorgan dissemination in mice.

55 ded: ischemic time, donor gender, donor age, multiorgan donation, center volume, extracorporeal membr

56 rior to the procurement of other organs in a multiorgan donor and hence prior to cross-clamp.

57 eased donor uterus procurement in a deceased multiorgan donor setting.

58 tients, four pancreatic cancer patients, one multiorgan donor, nine EL-Kras mice, and three N-nitroso

59 Each human islet isolated from 14 deceased multiorgan donors was cultured in Miami modified media-1

60 THODS.: Human pancreases were retrieved from multiorgan donors with appropriate consent.

61 hemical analysis in the exocrine pancreas of multiorgan donors with T1D (both at onset and at later s

62 er stages of the disease) and not in that of multiorgan donors with type 2 diabetes or nondiabetic do

63 everity (Atlanta criteria); subclassified as multiorgan dysfunction (MOF), pancreatic necrosis (PN >3

64 al 0.51-0.9, p=.03) as well as patients with multiorgan dysfunction (odds ratio 0.78, 95% confidence

65 tatistically significant in patients who had multiorgan dysfunction (odds ratio 0.82, 95% confidence

66 chanism in several human diseases, including multiorgan dysfunction after either massive red blood ce

67 an lead to clinical complications, including multiorgan dysfunction and even death.

68 S-CoV) infection caused severe pneumonia and multiorgan dysfunction and had a higher crude fatality r

69 Asl) deficiency has a distinct phenotype of multiorgan dysfunction and NO deficiency.

70 Sixty-seven percent of patients had multiorgan dysfunction at sepsis recognition, with 30% s

71 Timothy syndrome (TS) is a multiorgan dysfunction caused by a Gly to Arg substituti

72 mited by side effects, including reversible, multiorgan dysfunction characterized by a cytokine-induc

73 usion of aged stored blood may contribute to multiorgan dysfunction in susceptible patients.

74 syndrome, a novel disorder characterized by multiorgan dysfunction including lethal arrhythmias, web

75 d, most men and postmenopausal women develop multiorgan dysfunction marked by hepatic steatosis (chol

76 Spleen rupture (3 cases) and multiorgan dysfunction syndrome (3 cases) were the secon

77 of systemic inflammatory response syndrome, multiorgan dysfunction syndrome (MODS), and death.

78 Sepsis patients with multiorgan dysfunction syndrome and/or shock (original s

79 outcome measures were mortality, infections, multiorgan dysfunction syndrome, and acute respiratory d

80 a cytokine storm, overwhelming inflammation, multiorgan dysfunction, and death.

81 le line disruption may still lead to sepsis, multiorgan dysfunction, and increased mortality.

82 The MELD-XI score, a marker of multiorgan dysfunction, is a promising risk stratifier i

83 evalence, therapies used, new or progressive multiorgan dysfunction, ventilator- and vasoactive-free

84 period leading to systemic inflammation and multiorgan dysfunction.

85 cific disorder resulting in hypertension and multiorgan dysfunction.

86 ation to affect the development of shock and multiorgan dysfunction.

87 % subsequently developing new or progressive multiorgan dysfunction.

88 Also, because SM2(-/-) mice develop lethal multiorgan dysfunctions, we propose this regulatory prop

89 esult in local angiotensin II generation and multiorgan dysfunctions.

90 of nephrogenesis genes have been defined in multiorgan dysmorphic disorders in which renal dysplasia

91 ological state in which FGF23-alphaKlotho, a multiorgan endocrine network, is deranged in a self-ampl

92 longed aplasia (1), fungal pneumonia (1), or multiorgan failure (2).

93 The most common causes of death were multiorgan failure (26%), hemorrhagic stroke (24%), and

94 % TBSA group; p<0.0001), 154 (16%) developed multiorgan failure (increasing from 6% [ten] in the 30-3

95 (ACLF) is an ailment with high incidence of multiorgan failure (MOF) and consequent mortality.

96 Therefore, single-organ failure and/or multiorgan failure (MOF) are thought to contribute signi

97 e hepatic veno-occlusive disease (sVOD) with multiorgan failure (MOF) in patients who have received c

98 t respiratory distress syndrome (OR = 1.55), multiorgan failure (OR= 1.49), and death (OR = 1.74).

99 underwent liver-lung transplant, one died of multiorgan failure 11 days after transplant compared wit

100 d death (1.1%) occurred in a patient who had multiorgan failure 70 days after the last dose of NIVO p

101 was associated with increased postoperative multiorgan failure [42 (35%) vs 56 (20.4%), P = 0.001] a

102 e of UGIB in patients under AT are degree of multiorgan failure and comorbidity, but not AT itself.

103 syndrome (SIRS) and the events that lead to multiorgan failure and death are poorly understood.

104 ic disease with slow progression, leading to multiorgan failure and death, decades after its first cl

105 s caused by large-scale trauma that leads to multiorgan failure and death, despite the stemming of bl

106 y mechanical circulatory support may prevent multiorgan failure and death.

107 e can be associated with rapidly progressive multiorgan failure and devastating complications; howeve

108 ukopenia, and thrombocytopenia and developed multiorgan failure and hemorrhage.

109 coagulation, and immune systems, leading to multiorgan failure and shock, and thus, in some ways, re

110 iced, survival was related to the absence of multiorgan failure and to higher platelet counts.

111 anada, the United States, and Europe who had multiorgan failure and were receiving mechanical ventila

112 CSA was greater in patients who experienced multiorgan failure by day 7 (-15.7%; 95% CI, -27.7% to 1

113 by inactivating JNK and p38, thus preventing multiorgan failure caused by exaggerated inflammatory re

114 illness and was more severe among those with multiorgan failure compared with single organ failure.

115 ectively) and a significantly higher rate of multiorgan failure during the entire study (31 vs 17 eve

116 jury, chronic rejection, biliary sepsis, and multiorgan failure following retransplantation for prima

117 sis with rapidly progressive myocarditis and multiorgan failure from Ehrlichia chaffeensis in a previ

118 diseases such as bone marrow suppression and multiorgan failure have also been associated with HHV-8.

119 d lethal hemorrhagic fever with bleeding and multiorgan failure in human patients.

120 TGN1412 caused a massive cytokine storm and multiorgan failure in six healthy human volunteers.

121 Septicemia with multiorgan failure is associated with chronic activation

122 risk for systemic sepsis and, in some cases, multiorgan failure leading to death.

123 ntation as telomeropathy in adults, in which multiorgan failure may be prominent.

124 ochondrial dysfunction can occur and lead to multiorgan failure or death.

125 mphohistiocytosis and has been attributed to multiorgan failure or the use of nephrotoxic drugs, but

126 e to acute respiratory distress syndrome and multiorgan failure resulting in death, especially in ind

127 94%), a patient with liver cirrhosis died of multiorgan failure secondary to sodium overload.

128 rstitial lung disease and one as a result of multiorgan failure that occurred in the context of infec

129 systemic symptoms, lymphadenopathies, and/or multiorgan failure to rapidly document the diagnosis and

130 e of myocarditis, and one patient because of multiorgan failure with Guillain-Barre syndrome.

131 nvestigator (pneumonia, and septic shock and multiorgan failure).

132 ased susceptibility to secondary infections, multiorgan failure, and death.

133 slocates to the bloodstream, causing sepsis, multiorgan failure, and death.

134 d hyperoxia can lead to respiratory failure, multiorgan failure, and death.

135 r Charlson comorbidity index, and those with multiorgan failure, and similar in males and females.

136 organ damage, such as acute chest syndrome, multiorgan failure, and sudden death.

137 of the recipient, who died 10 weeks later of multiorgan failure, and unusual findings at autopsy.

138 verse events, one from dyspnoea and one from multiorgan failure, but neither was treatment related.

139 infarction, stroke and pulmonary embolism), multiorgan failure, head injury, and other.

140 y failure, respiratory infection, sepsis and multiorgan failure, ICU and hospital length of stay and

141 emic inflammatory response that evolves into multiorgan failure, leading to death.

142 emed treatment-related (pneumonia, two [2%]; multiorgan failure, one [1%]; and sepsis, one [1%], all

143 increased risk of cardiovascular events and multiorgan failure, the fundamental mechanisms underlyin

144 own origin, complicated by septic shock with multiorgan failure.

145 mortality among critically ill patients with multiorgan failure.

146 AMI VSR is advisable before establishment of multiorgan failure.

147 he patient with single LuTX died from septic multiorgan failure.

148 8 months, with 7 deaths caused by cardiac or multiorgan failure.

149 nd could be responsible for septic shock and multiorgan failure.

150 tant clinical outcomes, such as mortality or multiorgan failure.

151 iated with infection, hepatotoxicity, and/or multiorgan failure.

152 to a sudden loss of hepatic cells leading to multiorgan failure.

153 nt-related death secondary to sepsis-induced multiorgan failure.

154 reas leading causes of death were sepsis and multiorgan failure.

155 ignancy, and severe cutaneous reactions with multiorgan failure.

156 th included sepsis, right heart failure, and multiorgan failure.

157 ly but died in the postoperative period from multiorgan failure.

158 y ET and suggest that it causes death due to multiorgan failure.

159 scular complications that ultimately promote multiorgan failure.

160 atic disorder leading to heart, and possibly multiorgan failure.

161 to a rapidly fatal meningoencephalitis with multiorgan failure.

162 opposed, may result in tissue damage or even multiorgan failure.

163 ts/microL and albuminemia <35 g/L) died from multiorgan failure.

164 t who had a combination of syndromes died of multiorgan failure.

165 e control group [coronary artery disease and multiorgan failure] and three in the trastuzumab emtansi

166 ft-versus-host disease (cGVHD), resulting in multiorgan fibrosis and diminished function.

167 osis [SSc]), is characterized by progressive multiorgan fibrosis.

168 stead contributes to severe inflammation and multiorgan fibrotic disease.

169 hereas truncating mutations are found in the multiorgan form of Fraser syndrome.

170 al markers of patient recovery, for example, multiorgan function, infections, sepsis, and length of s

171 Tuberous sclerosis complex (TSC) is a multiorgan genetic disease caused by mutations in the TS

172 Tuberous sclerosis complex (TSC) is a multiorgan genetic disease in which brain involvement ca

173 By using multiorgan genome-wide analysis of aged mice, we found t

174 r 79% of combat-related injuries, leading to multiorgan hemorrhage and uncontrolled bleeding.

175 When tested in a model of blast trauma with multiorgan hemorrhaging, i.v. administration of the hemo

176 heparan sulfate proteoglycan, in modulating multiorgan host injury responses in murine endotoxemia.

177 A man in his mid-50s with multiorgan IgG4-RD developed progressive spastic hemipar

178 Autoimmune pancreatitis may belong to a multiorgan immunoglobulin G4-related autoimmune disease,

179 ases, causing local inflammation, fever, and multiorgan, including hepatic, dysfunction.

180 sclerosis, visceral congestion, hemorrhages, multiorgan infarcts, pyknotic neurons, and progressive s

181 ammatory autoimmune disease characterized by multiorgan infiltration of activated lymphocytes, high l

182 mice manifest autoimmunity characterized by multiorgan infiltration of activated T cells and high le

183 oxp3(+) regulatory T cells and develop fatal multiorgan inflammation (MOI) mediated by CD4(+) T cells

184 , IL-2 is potentially a master regulator for multiorgan inflammation and an underlying etiological fa

185 usly developed autoimmunity characterized by multiorgan inflammation and autoantibody production.

186 mice succumbed to systemic autoimmunity with multiorgan inflammation and autoantibody production.

187 nsgenic mice were partially rescued from the multiorgan inflammation and early lethality caused by th

188 These Tgfb1(C33S/C33S) mice develop multiorgan inflammation and tumors consistent with reduc

189 levels of IFN-gamma resulted in progressive multiorgan inflammation and two copies of the mutant all

190 are deficient in Tregs and succumb to severe multiorgan inflammation by 4 weeks of age.

191 inosine itself prolonged life and inhibited multiorgan inflammation by reducing Th1/Th2 cells and th

192 intain T cell homeostasis, as illustrated by multiorgan inflammation in mice deficient in TGF-beta1 s

193 y, Vbeta5(neg) T cells were able to transfer multiorgan inflammation in Rag1(-/-) recipients.

194 illus reuteri prolonged survival and reduced multiorgan inflammation in SF mice.

195 ent cpdm mice, which develop severe skin and multiorgan inflammation that has been hypothesized to be

196 hogenic T cells from B7-deficient mice cause multiorgan inflammation when adoptively transferred into

197 T cells from different individual LN induced multiorgan inflammation with comparable organ distributi

198 tor, lack regulatory T cells (Treg), develop multiorgan inflammation, and die prematurely.

199 of Tgfb1(-/-) mice (vasculogenesis defects, multiorgan inflammation, and lack of Langerhans cells) d

200 bal view of the interplays among Treg cells, multiorgan inflammation, hemopoiesis, and apoptosis.

201 Tgfb1(C33S/C33S) mice had multiorgan inflammation, lack of skin Langerhans cells (

202 d tissues, and its deletion in mice leads to multiorgan inflammation, splenomegaly, and premature dea

203 ative dermatitis mutation (Cpdm) mice causes multiorgan inflammation, yet this phenotype is not trans

204 se phenotype characterized by itchy skin and multiorgan inflammation.

205 sh movement, and subsequent lethality due to multiorgan inflammation.

206 ntral tolerance resulting in rapid and fatal multiorgan inflammation.

207 emic lupus erythematosus (SLE) is a chronic, multiorgan inflammatory autoimmune disorder associated w

208 cently shown to result in the development of multiorgan inflammatory disease and the resistance of re

209 Multiorgan inflammatory disease, spontaneous activation

210 3 regulatory T cells and suffer from a fatal multiorgan inflammatory disease.

211 ic deletion of TRAF6 unexpectedly results in multiorgan inflammatory disease.

212 The multiorgan inflammatory diseases associated with symptom

213 e dermatitis in mice (cpdm) is a spontaneous multiorgan inflammatory disorder with pathological hallm

214 us-like autoimmune syndrome characterized by multiorgan inflammatory lesions with a marked female pre

215 rprisingly, Malt1(PD/PD) animals developed a multiorgan inflammatory pathology, characterized by Th1

216 es and neutrophils in tissues and attenuated multiorgan injury and lethality.

217 l source of proinflammatory mediators drives multiorgan injury in response to AKI.

218 endothelial dysfunction that can progress to multiorgan injury, and severe cases are associated with

219 AKI) is frequently complicated by extrarenal multiorgan injury, including intestinal and hepatic dysf

220 iated with adverse cardiovascular events and multiorgan injury.

221 nt role of TGF-beta1 signaling in modulating multiorgan injury.

222 to determine the effect of TUDCA therapy on multiorgan insulin action and metabolic factors associat

223 Multiorgan insulin sensitivity before and after treatmen

224 atment markedly improved several measures of multiorgan insulin sensitivity, adipose tissue inflammat

225 Body composition, multiorgan insulin sensitivity, VLDL apolipoprotein B100

226 ucose tracer infusion, was used to determine multiorgan insulin sensitivity.

227 FF per patient correlated with the degree of multiorgan involvement (P = .014).

228 osis (ATTR) is a heterogeneous disorder with multiorgan involvement and a genetic or nongenetic basis

229 eveloped a lethal inflammatory disorder with multiorgan involvement and autoantibody production mimic

230 sistant nephrotic syndrome (SRNS) as part of multiorgan involvement but may also contribute to isolat

231 diverse genes that cause renal cysts and the multiorgan involvement of these diseases, multiple thera

232 Patient history, gene mutation, and multiorgan involvement were obtained from clinical recor

233 ong the connective tissue diseases for their multiorgan involvement, significant potential morbidity,

234 As JS is associated with multiorgan involvement, these patients should enter a di

235 was significantly lower among patients with multiorgan involvement.

236 re severe adverse drug-induced reaction with multiorgan involvement.

237 er patient was correlated with the degree of multiorgan involvement.

238 ed with TSC gene mutations and with brain or multiorgan involvement; their number per patient was cor

239 This microvascular thrombosis causes multiorgan ischemia with potentially life-threatening co

240 ubiquitin ligase Itch in mice caused massive multiorgan lymphocyte infiltration and skin lesions, chr

241 exocrine pancreatitis, hind limb paralysis, multiorgan lymphocyte infiltration, anti-nuclear antibod

242 at the initial stages of the process involve multiorgan metabolic interactions that produce a systemi

243 se concentration, comorbidity, mono-organ or multiorgan metastases, treatment line, and tumor progres

244 bly, we found that EETs stimulated extensive multiorgan metastasis and escape from tumor dormancy in

245 xorubicin treatment partially suppressed the multiorgan metastasis of 4T1 breast cancer cells in the

246 Multiorgan metastasis of drug-resistant 4T1 breast tumor

247 sulted in highly aggressive, angiogenic, and multiorgan metastatic tumors in nude mice.

248 months after kidney (n=37), liver (n=28), or multiorgan (n=5) transplant.

249 severe pan-nephritis, and/or severe systemic multiorgan necrotizing inflammation.

250 atic increase of circulating neutrophils and multiorgan neutrophil infiltration.

251 nce was associated with brain (P = .011) and multiorgan (P = .008) involvement.

252 ts in growth retardation, eye malformations, multiorgan pathologies, vascular defects, and neonatal d

253 ctance regulator (CFTR), is characterized by multiorgan pathology that begins early in life.

254 Multiorgan pharmacokinetics and accumulation in tumor ti

255 cohort (n = 232; 20.2%) with an unfavorable multiorgan phenotype across all 3 anatomic axes as compa

256 community cohort, identifies an unfavorable multiorgan phenotype associated with adverse health outc

257 3 anatomic axes as compared with a favorable multiorgan phenotype.

258 stic importance of computed tomography-based multiorgan phenotypes associated with adverse health out

259 ne functional magnetic resonance imaging and multiorgan physiological recording to dissect experience

260 ning-which is a powerful innate mechanism of multiorgan protection that can be induced by transient o

261 with multiple cGVHD organ involvement had a multiorgan response.

262 n-on-a-chip systems being designed to assess multiorgan responses to compounds.

263 treatment of the precipitant while providing multiorgan-supportive care that addresses the complex pa

264 Clinically, chronic GVHD is a pleiotropic, multiorgan syndrome involving tissue inflammation and fi

265 for this variant but are not affected by the multiorgan syndromes noted in the proband.

266 HD1 Notably, when mutated, these genes cause multiorgan syndromes that may include CAKUT as a feature

267 A multiorgan syndromic disorder characterized by siderobla

268 d immunoglobulin deposition are required for multiorgan system cGVHD and associated bronchiolitis obl

269 rodermatous cGVHD and an alloantibody-driven multiorgan system cGVHD model that induces bronchiolar o

270 ompatibility complex (MHC) mismatch model of multiorgan system cGVHD with bronchiolitis obliterans sy

271 liver disease should be considered part of a multiorgan system derangement in insulin sensitivity.

272 graft-versus-host-disease (cGVHD) can cause multiorgan system disease, typically with autoimmune-lik

273 MPs may contribute to the multiorgan system failure and high mortality of ALF.

274 The host injury involved in multiorgan system failure during severe inflammation is

275 hen left untreated, cardiovascular shock and multiorgan system failure ensue.

276 Hepa Wash was a safe procedure and improved multiorgan system failure in pigs with ALF.

277 Secondary outcomes, including multiorgan system failure, packed red blood cell transfu

278 ically ill patients suffering from sepsis or multiorgan system failure.

279 e frequently associated with polydactyly and multiorgan system involvement.

280 histocompatibility complex (MHC)-mismatched, multiorgan system model with BO, donor T-cell responses

281 methylmalonyl-CoA mutase (MUT) that exhibits multiorgan system pathology.

282 In a murine model of multiorgan system, nonsclerodermatous disease with bronc

283 lls (Tregs) essential for protection against multiorgan systemic autoimmunity.

284 Foxj1 deficiency resulted in multiorgan systemic inflammation, exaggerated Th1 cytoki

285 F-kappaB, with Foxd1 deficiency resulting in multiorgan, systemic inflammation, exaggerated Th cell-d

286 egulator transcription factor, which develop multiorgan T cell-mediated autoimmunity.

287 haracterized by high autoantibody levels and multiorgan tissue damage, including kidney and skin.

288 ion in B cells and with age developed severe multiorgan tissue inflammation.

289 medication-related complications, including multiorgan toxicities and systemic side effects.

290 ered systemically and carry inherent risk of multiorgan toxicities.

291 ood cell (WBC) transcriptome to the general, multiorgan transcriptome.

292 In a prior multiorgan transplant database study, recipient Epstein-

293 Multiorgan transplantation allocation may not be congrue

294 United Network for Organ Sharing multiorgan transplantation allocation policy allows sequ

295 ith pretransplantation diabetes mellitus and multiorgan transplantation were excluded.

296 ) in the previous 3 months, and simultaneous multiorgan transplantation.

297 Multiorgan transplantations, split grafts, or non-heart-

298 We excluded multiorgan transplants and living donor transplantation.

299 models are identified, and single-organ and multiorgan transplants are defined, then each risk adjus

300 phenolate immunosuppression and did not have multiorgan transplants.